Predict your next investment

HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research

See what CB Insights has to offer

Founded Year



Acquired | Acquired

About CSI Laboratories

CSI Laboratories offers flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, molecular genetics, sequencing, and consultations to hematopathology and surgical pathology clients. It is independently owned and operated by medical professionals, providing diagnostic testing and rapid turnaround times for clients across the United States.On August 9th, 2021, CSI Laboratories was acquired by Fulgent Genetics. Terms of the transaction were not disclosed.

CSI Laboratories Headquarter Location

2580 Westside Parkway

Alpharetta, Georgia, 30004,

United States


Latest CSI Laboratories News

Fulgent Sets Cancer Testing Deals

Aug 16, 2021

Fulgent is preparing for a post-Covid future. In attempts to secure its future once the Covid testing bonanza subsides, Temple City-based genetic testing company Fulgent Genetics Inc. announced two deals with cancer testing companies Aug. 9. In conjunction with the company’s quarterly earnings report, Fulgent said it had acquired Alpharetta, Ga.-based molecular diagnostics and cancer testing company CSI Laboratories for an undisclosed sum. Fulgent also announced a partnership with early cancer screening company Helio Health, a unit of Irvine-based Helio Inc., to commercialize Helio’s blood sample-based early cancer detection technology. CSI Laboratories, which was founded in 1997, offers more than 400 unique cancer diagnostic tests using a variety of technologies, including the use of fluorescent probes and chromosome sample testing. Fulgent’s goal in acquiring CSI Laboratories is to expand its capability to test tumor samples for malignancy and expand its molecular diagnostics offerings. Fulgent is also planning to integrate CSI Laboratories’ technologies into a new cancer testing lab in California. “We expect CSI will serve as an anchor to Fulgent’s cancer testing capabilities, bringing their expertise and experience to a national oncologic centered client base, and expanding their broad pathology and molecular offerings by leveraging Fulgent’s leadership in next generation (genetic) sequencing,” Larry Weiss, Fulgent’s chief medical officer, said in a statement. The partnership with Helio Inc. makes Fulgent a contender in the race to develop accurate early cancer detection tests from blood samples — a much less invasive diagnostic technology than the traditional tissue biopsy. Another local company, Santa Monica-based Quantgene Inc., is developing similar technology. The Fulgent-Helio partnership will focus first on commercializing Helio’s technology to detect liver cancer from blood samples, which is undergoing clinical trials in the United States and China, according to the announcement. “Helio has demonstrated that its liquid biopsy test offers significantly better accuracy relative to other test methods for early cancer detection,” Weiss said. As for Fulgent’s earnings, the company on Aug. 9 reported second-quarter revenue of $153.6 million, a 790% increase over second quarter 2020, just before Fulgent entered the Covid testing market. Fulgent’s non-Covid testing revenue also rose nearly 300% to $25.7 million. According to website Seeking Alpha, Fulgent’s revenue fell $44 million short of analysts’ consensus estimates. Fulgent’s net income for the quarter was $79.8 million, up from $3.3 million in second- quarter 2020.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CSI Laboratories

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CSI Laboratories is included in 2 Expert Collections, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

CSI Laboratories Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CSI Laboratories Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.